1. Copyright © 2014 American Medical Association. All rights reserved.
From: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusA Meta-analysis
JAMA Intern Med. 2014;174(5): doi: /jamainternmed
Figure Legend:
Flowchart of Article Selection for Meta-analysisPotentially relevant reports identified and screened for retrieval. ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.
Date of download: 11/9/2017
Copyright © 2014 American Medical Association. All rights reserved.

2. Copyright © 2014 American Medical Association. All rights reserved.
From: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusA Meta-analysis
JAMA Intern Med. 2014;174(5): doi: /jamainternmed
Figure Legend:
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and All-Cause Mortality Stratified by Comparison Group (Placebo vs Active)Diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes, the weight of individual studies in the pooled analysis. Trials to the left of the vertical line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental intervention. M-H indicates Mantel-Haenszel. See Table 1 footnote for expansion of clinical trial acronyms.
Date of download: 11/9/2017
Copyright © 2014 American Medical Association. All rights reserved.

3. Copyright © 2014 American Medical Association. All rights reserved.
From: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusA Meta-analysis
JAMA Intern Med. 2014;174(5): doi: /jamainternmed
Figure Legend:
Angiotensin II Receptor Blockers (ARBs) and All-Cause Mortality Stratified by Comparison Group (Placebo vs Active)Diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes, the weight of individual studies in the pooled analysis. Trials to the left of the vertical line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental intervention. M-H indicates Mantel-Haenszel. See Table 1 footnote for expansion of clinical trial acronyms.
Date of download: 11/9/2017
Copyright © 2014 American Medical Association. All rights reserved.

4. Copyright © 2014 American Medical Association. All rights reserved.
From: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusA Meta-analysis
JAMA Intern Med. 2014;174(5): doi: /jamainternmed
Figure Legend:
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Cause-Specific Cardiovascular OutcomesDiamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes, the weight of individual studies in the pooled analysis. Trials to the left of the vertical line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental intervention. M-H indicates Mantel-Haenszel. See Table 1 footnote for expansion of clinical trial acronyms.
Date of download: 11/9/2017
Copyright © 2014 American Medical Association. All rights reserved.

5. Copyright © 2014 American Medical Association. All rights reserved.
From: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusA Meta-analysis
JAMA Intern Med. 2014;174(5): doi: /jamainternmed
Figure Legend:
Angiotensin II Receptor Blockers (ARBs) and Cause-Specific Cardiovascular (CV) OutcomesDiamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes, the weight of individual studies in the pooled analysis. Trials to the left of that line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental intervention. M-H indicates Mantel-Haenszel. See Table 1 footnote for expansion of clinical trial acronyms.
Date of download: 11/9/2017
Copyright © 2014 American Medical Association. All rights reserved.